DNTH

Dianthus Therapeutics, Inc. /DE/

SEC CIK 1690585
$81.89 +55.4% · 90 days
90-day buys
$0
0 open-market
90-day sells
$14.89M
15 open-market
Net insider flow
−$14.89M
Net selling
Filings shown
57
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at DNTH have sold a net $14.89M of stock (0 open-market buys vs 15 sells).

Largest recent trade: Garcia Marino sold $5.36M of DNTH, trimming their stake 83%.

Most active filer: Randhawa Simrat, with 21 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for DNTH, newest first
View on SEC EDGAR ↗
DNTH
Sell Garcia Marino · Director, CEO AND PRESIDENT · Open-market sale · filed Mar 13, 2026 ΔOwn −92%

Garcia Marino sold $1.06M of DNTH, trimming their stake 92%.

−$1.06M
12,796 sh @ $83
DNTH
Sell Garcia Marino · Director, CEO AND PRESIDENT · Open-market sale · filed Mar 13, 2026 ΔOwn −18%

Garcia Marino sold $16.7K of DNTH, trimming their stake 18%.

−$16.7K
200 sh @ $83
DNTH
Sell Garcia Marino · Director, CEO AND PRESIDENT · Open-market sale · filed Mar 13, 2026 ΔOwn −100%

Garcia Marino sold $77K of DNTH, trimming their stake 100%.

−$77K
900 sh @ $86
Advertisement
DNTH
Sell CARR EDWARD · CHIEF ACCOUNTING OFFICER · Open-market sale · filed Mar 13, 2026 ΔOwn −36%

Carr Edward sold $1.28M of DNTH, trimming their stake 36%.

−$1.28M
15,852 sh @ $81
DNTH
Sell CARR EDWARD · CHIEF ACCOUNTING OFFICER · Open-market sale · filed Mar 13, 2026 ΔOwn −84%

Carr Edward sold $1.92M of DNTH, trimming their stake 84%.

−$1.92M
23,465 sh @ $82
DNTH
Sell CARR EDWARD · CHIEF ACCOUNTING OFFICER · Open-market sale · filed Mar 13, 2026 ΔOwn −89%

Carr Edward sold $319.5K of DNTH, trimming their stake 89%.

−$319.5K
3,865 sh @ $83
DNTH
Sell CARR EDWARD · CHIEF ACCOUNTING OFFICER · Open-market sale · filed Mar 13, 2026 ΔOwn −40%

Carr Edward sold $16.7K of DNTH, trimming their stake 40%.

−$16.7K
200 sh @ $83
DNTH
Sell CARR EDWARD · CHIEF ACCOUNTING OFFICER · Open-market sale · filed Mar 13, 2026 ΔOwn −100%

Carr Edward sold $25.7K of DNTH, trimming their stake 100%.

−$25.7K
300 sh @ $86
Advertisement

About DNTH insider activity

This page tracks every recent Form 4 filed for Dianthus Therapeutics, Inc. /DE/ with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is DNTH insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Dianthus Therapeutics, Inc. /DE/ usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.